These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 30459318)

  • 1. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
    Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
    Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
    Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
    Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
    Lee SK; Hwang JH; Choi KY
    Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
    Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
    Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.
    Cha PH; Cho YH; Lee SK; Lee J; Jeong WJ; Moon BS; Yun JH; Yang JS; Choi S; Yoon J; Kim HY; Kim MY; Kaduwal S; Lee W; Min do S; Kim H; Han G; Choi KY
    Nat Chem Biol; 2016 Aug; 12(8):593-600. PubMed ID: 27294323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling.
    Shin W; Lee SK; Hwang JH; Park JC; Cho YH; Ro EJ; Song Y; Seo HR; Choi KY
    Exp Mol Med; 2018 Jun; 50(6):1-10. PubMed ID: 29884842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P; Li X; Zhang R; Liu S; Xiang Y; Zhang M; Chen X; Pan T; Yan L; Feng J; Duan T; Wang D; Chen B; Jin T; Wang W; Chen L; Huang X; Zhang W; Sun Y; Li G; Kong L; Chen X; Li Y; Yang Z; Zhang Q; Zhuo L; Sui X; Xie T
    Theranostics; 2020; 10(11):5107-5119. PubMed ID: 32308771
    [No Abstract]   [Full Text] [Related]  

  • 10. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H; Liu Y; Wu K; Luo H; Cui L
    Cell Commun Signal; 2020 Jul; 18(1):115. PubMed ID: 32703218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.
    Cha PH; Choi KY
    BMB Rep; 2016 Sep; 49(9):455-6. PubMed ID: 27470214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells.
    Cho YH; Ro EJ; Yoon JS; Kwak DK; Cho J; Kang DW; Lee HY; Choi KY
    Cell Commun Signal; 2020 Mar; 18(1):38. PubMed ID: 32143715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer.
    Yang L; Bhattacharya A; Li Y; Sexton S; Ling X; Li F; Zhang Y
    J Exp Clin Cancer Res; 2022 Jun; 41(1):184. PubMed ID: 35650607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
    Kim S; Kim N; Kang K; Kim W; Won J; Cho J
    Cells; 2019 Aug; 8(8):. PubMed ID: 31409052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Honokiol enhances the sensitivity of cetuximab in KRAS
    Zhu Q; Zhang R; Gu X; Zhao Z; Gao Q; Chen M; Wu Q; Xie T; Sui X
    Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106
    [No Abstract]   [Full Text] [Related]  

  • 17. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Catenin-RAS interaction serves as a molecular switch for RAS degradation via GSK3β.
    Lee SK; Jeong WJ; Cho YH; Cha PH; Yoon JS; Ro EJ; Choi S; Oh JM; Heo Y; Kim H; Min DS; Han G; Lee W; Choi KY
    EMBO Rep; 2018 Dec; 19(12):. PubMed ID: 30413483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
    Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.